Cbfa-1 (Runx-2) and Osteocalcin Expression by Human Osteoblasts in Heparin Osteoporosis in Vitro

Abstract

Heparin may cause adverse effects on bone formation following long-term application. The exact pathomechanism is unclear, but in vitro data suggest an impaired osteoblast function. The transcription axis of Cbfa-1 (Runx-2) and osteocalcin is crucial in maintaining an equilibrium of bone formation and resorption in vivo. We used a human osteoblast cell culture model to further investigate the effect of heparin (low-molecular-weight heparin, dalteparin) on the expression of these two regulators of osteoblast differentiation. At high doses, dalteparin caused a significant inhibition of both osteocalcin and Cbfa-1 expression in vitro. Our data support the hypothesis of a direct inhibition of osteoblast function underlying heparin osteoporosis.

Keywords

Heparin osteoporosis Osteoblast Osteocalcin Cbfa-1

References

Griffith GC , Nichols G , Asher J , et al. Heparin osteoporosis. JAMA 1965; 193: 91-91.

Squires JW , Pinch LW. Heparin-induced spinal fractures. JAMA 1979; 241: 2417-2417.

Wise PH , Hall AJ. Heparin-induced osteopenia in pregnancy. BMJ 1980; 281: 110-110.

Megard M , Cuche M , Grapeloux A. Heparin osteoporosis: Histomorphometric analyis of bone biopsy. Nouv Presse Med. 1982; 11: 261-261.

Dahlmann TC. Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol 1993; 168: 1265-1265.

Sivakumaran M , Ghosh K , Zaidi Y , et al. Osteoporosis and vertebral collapse following low-dose, low-molecular-weight heparin therapy in a young patient. Clin Lab Haematol 1996; 18: 55-55.

Douketis JD , Ginsberg JS , Burrows RF , et al. The effect of long-term heparin therapy during pregnancy on bone density. A prospective matched cohort study. Thromb Haemost 1996; 75: 254-254.

Hunt BJ , Doughty HA , Majumdar G , et al. Thromboprophylaxis with low-molecular-weight heparin (Fragmin) in high-risk pregnancies. Thromb Haemost 1997; 77: 39-39.

Wawrzynska L , Tomkowski WZ , Przedlacki J , et al. Changes in bone density during long-term administration of low-molecular-weight heparins or acenocoumarol for secondary prophylaxis of venous thromboembolism. Pathophysiol Haemost Thromb 2003; 33: 64-64.

10.

Kock HJ , Handschin AE. Osteoblast growth inhibition by unfractionated and by low-molecular-weight heparins: An in-vitro investigation. Clin Appl Thromb Hemost 2002; 8: 251-251.

11.

Walton KJ , Duncan JM , Deschamps P , et al. Heparin acts synergistically with interleukin-11 to induce STAT3 activation and in vitro osteoclast formation. Blood 2002; 100: 2530-2530.

12.

Bhandari M , Hirsh J , Weitz JI , et al. The effects of standard and low-molecular-weight heparin on bone nodule formation in vitro. Thromb Hemost 1998; 80: 413-413.

13.

Handschin AE , Trentz OA , Hoerstrup SP , et al. Effect of low-molecular-weight heparin (dalteparin) and fondaparinux (Arixtra®) on human osteoblasts in vitro. Br J Surg 2005; 92: 177-177.

14.

Ducy P , Desbois C , Boyce B , et al. Increased bone formation in osteocalcin-deficient mice. Nature 1996; 382: 448-448.

15.

Lian JB , Javed A , Zaidi SK , et al. Regulatory controls for osteoblast growth and differentiation: Role of Runx/Cbfa/AML factors. Crit Rev Eukaryot Gene Expr 2004; 14: 1-1.

16.

Lian JB , Stein GS. Runx2/Cbfa1: A multifunctional regulator of bone formation. Curr Pharm Des 2003; 9: 2677-2677.

17.

Ducy P. Cbfa-1: A molecular switch in osteoblast biology. Dev Dyn 2000; 219: 461-461.

18.

Ducy P , Zhang R , Geoffroy V , et al. Osf2/Cbfa-1: A transcriptional activator of osteoblast differentiation. Cell 1997; 89: 747-747.

19.

Trentz OA , Hoerstrup SP , Sun LK , et al. Osteoblasts response to allogenic and xenogenic solvent dehydrated cancellous bone in vitro. Biomaterials 2003; 24: 3417-3417.

20.

Mocellin S , Rossi CR , Pilati P , et al. Quantitative real-time PCR: A powerful ally in cancer research. Trends Mol Med 2003; 9: 189-189.

21.

Prophet EB , Mills B , Arrington JB , Sobin LH , eds. Laboratory Methods in Histotechnology of the Armed Forces Institute of Pathology, 4th ed., Washington DC: American Registry of Pathology, 1992.

22.

Aronow MA , Gerstenfeld LC , Owen TA , et al. Factors that promote progressive development of the osteoblast phenotype in cultured fetal rat calvaria cells. J Cell Physiol 1990; 143: 213-213.

23.

Trentz OA , Handschin AE , Bestman L , et al. Influence of brain injury on early posttraumatic bone metabolism. Crit Care Med 2005; 33: 399-399.

24.

Banerjee C , et al. Differential regulation of two principal Runx2/Cbfa-1 n-terminal isoforms in response to bone morphogenetic protein-2 during development of the osteoblast phenotype. Endocrinology 2001; 142: 4026-4026.

25.

Komori T , Yagi H , Nomura S , et al. Targeted disruption of Cbfa-1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 1997; 89: 755-755.

26.

Otto F , Thornell AP , Crompton T , et al. Cbfa-1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 1997; 89: 765-765.

27.

Liu W , Toyosawa S , Furuichi T , et al. Overexpression of Cbfa-1 in osteoblasts inhibits osteoblast maturation and causes osteopenia with multiple fractures. J Cell Biol 2001; 155: 157-157.

28.

Phan TC , Xu J , Zheng MH. Interaction between osteoblast and osteoclast: Impact in bone disease. Histol Histopathol 2004; 19: 1325-1325.

29.

Fuller K , Chambers TJ , Gallagher AC. Heparin augments osteoclast resorption-stimulating activity in serum. J Cell Physiol 1991; 147: 208-208.

30.

Hauser HJ , Brenner RE. Low doses and high doses of heparin have different effects on osteoblast-like Saos-2 cells in vitro. J Cell Biochem 2004; 91: 1062-1062.

31.

Pautke C , Schieker M , Tischer T. Characterization of osteosarcoma cell lines MG-63, Saos-2 and U-2 OS in comparison to human osteoblasts. Anticancer Res 2004; 24: 3743-3743.

32.

Dahl OE , Pleil AM. Investment in prolonged thromboprophylaxis with dalteparin improves clinical outcomes after hip replacement. J Thromb Haemost 2003; 1: 896-896.

33.

Kolb G , Bodamer I , Galster H , et al. Reduction of venous thromboembolism following prolonged prophylaxis with the low-molecular-weight heparin Certoparin after endo-prosthetic joint replacement or osteosynthesis of the lower limb in elderly patients. Thromb Haemost 2003; 90: 1100-1100.